logo

GNFT

Genfit
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
consensus rating "Strong Buy"
Hanging Man
Bearish Abandoned Baby

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About GNFT

Genfit S.A.

A late-stage biopharmaceutical company that develops therapeutic diagnostic solutions for metabolic liver-related diseases

Pharmaceutical
Invalid Date
03/27/2019
NASDAQ Stock Exchange
159
12-31
Depository Receipts (Ordinary Shares)
Parc Eurasante, 885, avenue Eugene Avinee, 59120 Loos, France
--
Genfit S.A. is a late-stage clinical biopharmaceutical company dedicated to the discovery and development of innovative drug candidates and diagnostic solutions for metabolic and liver-related diseases, where there are considerable unmet medical needs. They are leaders in nuclear receptor-based drug discovery with a rich history of nearly 20 years and a strong scientific legacy.

Company Financials

EPS

GNFT has released its 2022 Q2 earnings. EPS was reported at -0.23, versus the expected 0.00, missing expectations. The chart below visualizes how GNFT has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime